{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:22:28Z","timestamp":1791829348478,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.aohep.2025.102169","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T16:06:19Z","timestamp":1766592379000},"page":"102169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-5480","authenticated-orcid":false,"given":"Stephen Lam","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-7741","authenticated-orcid":false,"given":"Julien","family":"Edeline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadahisa","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3474-6647","authenticated-orcid":false,"given":"Jennifer J.","family":"Knox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baek-Yeol","family":"Ryoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Merle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3919-4135","authenticated-orcid":false,"given":"Mohamed","family":"Bouattour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Yeong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Anne","family":"Haber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby B.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Chin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4102-3474","authenticated-orcid":false,"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Lii","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.aohep.2025.102169_bib0001","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.aohep.2025.102169_bib0002","doi-asserted-by":"crossref","first-page":"332","DOI":"10.5009\/gnl15257","article-title":"Epidemiology of hepatocellular carcinoma in the Asia-Pacific Region","volume":"10","author":"Zhu","year":"2016","journal-title":"Gut Liver"},{"issue":"3","key":"10.1016\/j.aohep.2025.102169_bib0003","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/jgh3.12275","article-title":"Epidemiological differences of common liver conditions between Asia and the West","volume":"4","author":"Jayaraman","year":"2020","journal-title":"JGH Open"},{"issue":"12","key":"10.1016\/j.aohep.2025.102169_bib0004","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1002\/ijc.21731","article-title":"The global health burden of infection-associated cancers in the year 2002","volume":"118","author":"Parkin","year":"2006","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.aohep.2025.102169_bib0005","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"issue":"19","key":"10.1016\/j.aohep.2025.102169_bib0006","doi-asserted-by":"crossref","first-page":"11363","DOI":"10.3390\/ijms231911363","article-title":"Challenges and future trends of hepatocellular carcinoma immunotherapy","volume":"23","author":"Rizzo","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.aohep.2025.102169_bib0007","first-page":"352","article-title":"Associations between \u201ccancer risk\u201d, \u201cinflammation\u201d and \u201cmetabolic syndrome\u201d: a scoping review","volume":"13","author":"Vitale","year":"2024","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.aohep.2025.102169_bib0008","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.4_suppl.518","article-title":"Updated efficacy and safety of KEYNOTE-224: a phase II study of Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC). In: 518, editor","author":"Kudo","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.aohep.2025.102169_bib0009","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa Ghassan","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.aohep.2025.102169_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.02.009","article-title":"Updated efficacy and safety of KEYNOTE-224: a phase II study of Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib","volume":"167","author":"Kudo","year":"2022","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.aohep.2025.102169_bib0011","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1158\/1078-0432.CCR-21-3807","article-title":"Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: data from the open-label, phase II KEYNOTE-224 trial","volume":"28","author":"Verset","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.aohep.2025.102169_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061680","article-title":"Systemic therapy for advanced hepatocellular carcinoma: current stand and perspectives","volume":"15","author":"Girardi","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.aohep.2025.102169_bib0013","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000529636","article-title":"Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: longer term follow-up from the phase 3 KEYNOTE-240 trial","volume":"12","author":"Merle","year":"2023","journal-title":"Liver Cancer"},{"issue":"6","key":"10.1016\/j.aohep.2025.102169_bib0014","first-page":"655","article-title":"Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma with main trunk and\/or contralateral portal vein invasion in IMbrave150","volume":"13","author":"Finn","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.aohep.2025.102169_bib0015","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update","author":"Gordan","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.aohep.2025.102169_bib0016","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.annonc.2024.03.005","article-title":"Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040","volume":"35","author":"Melero","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.aohep.2025.102169_bib0017","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.aohep.2025.102169_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","author":"Rimassa","year":"2025","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2025.102169_bib0019","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann Oncol"},{"issue":"10492","key":"10.1016\/j.aohep.2025.102169_bib0020","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.aohep.2025.102169_bib0021","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/annonc\/mdh430","article-title":"Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy","volume":"15","author":"Yeo","year":"2004","journal-title":"Ann Oncol"},{"issue":"10088","key":"10.1016\/j.aohep.2025.102169_bib0022","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2025.102169_bib0023","first-page":"5985131","article-title":"A rare case of pembrolizumab-induced reactivation of hepatitis b","volume":"2018","author":"Pandey","year":"2018","journal-title":"Case Rep Oncol Med"},{"issue":"1","key":"10.1016\/j.aohep.2025.102169_bib0024","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s40425-019-0808-5","article-title":"Hepatitis B virus reactivation in cancer patients with positive hepatitis B surface antigen undergoing PD-1 inhibition","volume":"7","author":"Zhang","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.aohep.2025.102169_bib0025","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019013","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with HBV\/HCV infection and advanced-stage cancer: a systematic review","volume":"99","author":"Pu","year":"2020","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.aohep.2025.102169_bib0026","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001072","article-title":"Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma","volume":"8","author":"Lee","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.aohep.2025.102169_bib0027","unstructured":"Merck & Co I. KEYTRUDA\u00ae(pembrolizumab) injection, for intravenous use. 2025 03\/11\/2025:[164 p]. Available from https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf."},{"issue":"7","key":"10.1016\/j.aohep.2025.102169_bib0028","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.aohep.2025.102169_bib0029","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase iii trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.aohep.2025.102169_bib0030","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1200\/JCO.22.00620","article-title":"Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: a randomized, double-blind, phase III trial","volume":"41","author":"Qin","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.aohep.2025.102169_bib0031","doi-asserted-by":"crossref","unstructured":"Finn RS, Kudo M, Borbath I, Edeline J, Cattan S, Van Vlierberghe H, et al. Pembrolizumab (pembro) in patients (pts) with sorafenib-treated (cohort 1) and treatment (tx)-naive (cohort 2) advanced hepatocellular carcinoma (aHCC) after additional follow-up in the phase 2 KEYNOTE-224 study. J Clin Oncol 2024;42(16_suppl). 2024\/06\/014100-00. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4100.","DOI":"10.1200\/JCO.2024.42.16_suppl.4100"},{"key":"10.1016\/j.aohep.2025.102169_bib0032","first-page":"737389","article-title":"PD-1 blockade in advanced melanoma in patients with hepatitis c and\/or hiv","volume":"2015","author":"Davar","year":"2015","journal-title":"Case Rep Oncol Med"},{"issue":"2","key":"10.1016\/j.aohep.2025.102169_bib0033","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CMR.0000000000000434","article-title":"Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series","volume":"28","author":"Kothapalli","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.aohep.2025.102169_bib0034","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2018.09.017","article-title":"Anti-PD-1\/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B\/C infection","volume":"104","author":"Tio","year":"2018","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.aohep.2025.102169_bib0035","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s40425-019-0771-1","article-title":"Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection","volume":"7","author":"Shah","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.aohep.2025.102169_bib0036","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3389\/fimmu.2020.01037","article-title":"Anti-PD-1\/PD-L1 blockade immunotherapy employed in treating Hepatitis B virus infection-related advanced hepatocellular carcinoma: a literature review","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.aohep.2025.102169_bib0037","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3389\/fcimb.2019.00207","article-title":"The PD-1\/PD-L1 axis and virus infections: a delicate balance","volume":"9","author":"Sch\u00f6nrich","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"10.1016\/j.aohep.2025.102169_bib0038","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhepr.2019.06.001","article-title":"HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection","volume":"1","author":"Ferrando-Martinez","year":"2019","journal-title":"JHEP Reports: Innovation Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2025.102169_bib0039","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J Hepatol"},{"issue":"7077","key":"10.1016\/j.aohep.2025.102169_bib0040","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.aohep.2025.102169_bib0041","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/j.gastro.2015.11.050","article-title":"Hepatitis B virus\u2013specific and global T-cell dysfunction in chronic hepatitis B","volume":"150","author":"Park","year":"2016","journal-title":"Gastroenterol"},{"issue":"1","key":"10.1016\/j.aohep.2025.102169_bib0042","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2025.102169_bib0043","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1053\/j.gastro.2019.01.271","article-title":"Hepatitis C Virus infection in patients with cancer: impact on clinical trial enrollment, selection of therapy, and prognosis","volume":"157","author":"Torres","year":"2019","journal-title":"Gastroenterol"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268125003941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268125003941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:51:34Z","timestamp":1780649494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268125003941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1665268125003941"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2025.102169","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2025.102169","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C.","name":"copyright","label":"Copyright"}],"article-number":"102169"}}